Endothelial Dysfunction in Hematopoietic Cell Transplantation

Clin Hematol Int. 2019 Mar 18;1(1):45-51. doi: 10.2991/chi.d.190317.001. eCollection 2019 Mar.

Abstract

The goal of this review is to look at the role of endothelial damage and dysfunction in the initiation and development of early complications that appear after hematopoietic cell transplantation (HCT). These early complications share overlapping clinical manifestations and the suspicion of underlying endothelial damage. Several studies using different approaches, such as animal and in vitro models, the analysis of soluble biomarkers and clinical findings have provided evidence of this endothelial dysfunction. Historically, the first complication in which the role of endothelial damage was elucidated was the veno-oclusive disease/sinusoidal obstructive syndrome. In the last two decades, increasing evidence of the implication of the endothelium in the pathophysiology of other syndromes such as capillary leak syndrome, transplant-associated microangiopathy, or even graft versus host disease has accumulated. This knowledge opens up potential pharmacologic interventions to prevent/and/or treat endothelial damage and, therefore, to improve the outcome of patients receiving HCT.

Keywords: Endohtelium; Endothelial dysfunction; GvHD; Hematopoietic stem cell transplantation; Inflammation; TA-TMA.

Publication types

  • Review